

**Published, ongoing & planned projects**

Last update: 22.11.2021

Title	Status	No.	Year	Download/Link
<b>HTA Project Reports</b>				
Therapeutic conversation: The effectiveness of intensified physician-patient communication	published	1	2006	<a href="http://eprints.hta.lbg.ac.at/22/">http://eprints.hta.lbg.ac.at/22/</a>
Horizon Scanning System (HSS) - An Overview	published	2	2006	<a href="http://eprints.hta.lbg.ac.at/586/">http://eprints.hta.lbg.ac.at/586/</a>
External manual. Part 1	published	3	2007	<a href="http://eprints.hta.lbg.ac.at/714/">http://eprints.hta.lbg.ac.at/714/</a>
Neonatal care of low-risk newborns. An approach to evidence-based health care planning in Styria	published	4	2007	<a href="http://eprints.hta.lbg.ac.at/693/">http://eprints.hta.lbg.ac.at/693/</a>
Role and positioning of university outpatient departments	published	5	2007	<a href="http://eprints.hta.lbg.ac.at/38/">http://eprints.hta.lbg.ac.at/38/</a>
Internal manual. Part 2 (2nd Ed.)	published	6	2009	<a href="http://eprints.hta.lbg.ac.at/713/">http://eprints.hta.lbg.ac.at/713/</a>
Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes	published	7	2007	<a href="http://eprints.hta.lbg.ac.at/715/">http://eprints.hta.lbg.ac.at/715/</a>
Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice	published	8	2007	<a href="http://eprints.hta.lbg.ac.at/716/">http://eprints.hta.lbg.ac.at/716/</a>
Economic evaluation of HPV vaccination in Austria	published	9	2007	<a href="http://eprints.hta.lbg.ac.at/760/">http://eprints.hta.lbg.ac.at/760/</a>
Economic aspects of clinically effective and efficient models of health services in alcohol addiction treatment - Part I: International models and approaches of outcome measurement, Part 2: Selected models of integrated care and their evaluation, Part 3: ongoing	published	10	2009	<a href="http://eprints.hta.lbg.ac.at/823/">http://eprints.hta.lbg.ac.at/823/</a>
Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies	published	11	2008	<a href="http://eprints.hta.lbg.ac.at/788/">http://eprints.hta.lbg.ac.at/788/</a>
Back pain. Diagnosis and treatment according to evidence-based guidelines - options and limitations.	published	12	2008	<a href="http://eprints.hta.lbg.ac.at/794/">http://eprints.hta.lbg.ac.at/794/</a>
Clinical application of Tissue Engineering. An overview of International and Austrian Areas of Research with a critical analysis of selected applications	published	13	2008	<a href="http://eprints.hta.lbg.ac.at/807/">http://eprints.hta.lbg.ac.at/807/</a>
Horizon Scanning in Oncology - Concept Development for the Preparation of a Horizon Scanning System in Austria	published	14	2008	<a href="http://eprints.hta.lbg.ac.at/798/">http://eprints.hta.lbg.ac.at/798/</a>
Outpatient Cardiac Rehabilitation. Part 1: Evaluation and Indicators. Part 2: Comparative analysis of various rehabilitation models and Phase III	published	15	2008	<a href="http://eprints.hta.lbg.ac.at/800/">http://eprints.hta.lbg.ac.at/800/</a>
Clinical Pathways: Systematic Review of outcome parameters and effectiveness	published	16	2008	<a href="http://eprints.hta.lbg.ac.at/801/">http://eprints.hta.lbg.ac.at/801/</a>
Clavicular Fractures - A systematic review about efficacy and safety of different treatment options	published	17	2008	<a href="http://eprints.hta.lbg.ac.at/816/">http://eprints.hta.lbg.ac.at/816/</a>
Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part 2 of the project 'Statins: A comparison between predicted and actual effects on population health in Austria)	published	18	2008	<a href="http://eprints.hta.lbg.ac.at/803/">http://eprints.hta.lbg.ac.at/803/</a>
Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part 3 of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria').	published	19	2008	<a href="http://eprints.hta.lbg.ac.at/804/">http://eprints.hta.lbg.ac.at/804/</a>
Folic acid fortification of flour in Austria - Risks and benefits	published	20	2009	<a href="http://eprints.hta.lbg.ac.at/847/">http://eprints.hta.lbg.ac.at/847/</a>
Evidence supported health service planning	published	21	2009	<a href="http://eprints.hta.lbg.ac.at/843/">http://eprints.hta.lbg.ac.at/843/</a>
Reimbursement processes – An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems	published	22	2008	<a href="http://eprints.hta.lbg.ac.at/817/">http://eprints.hta.lbg.ac.at/817/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 1: instruments for stroke and traumatic brain injury	published	23a	2009	<a href="http://eprints.hta.lbg.ac.at/866/">http://eprints.hta.lbg.ac.at/866/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 2: International experiences with quality / performance assessments and reimbursement	published	23b	2009	<a href="http://eprints.hta.lbg.ac.at/867/">http://eprints.hta.lbg.ac.at/867/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 3: Status quo s in Austria	published	23c	2010	<a href="http://eprints.hta.lbg.ac.at/879/">http://eprints.hta.lbg.ac.at/879/</a>
Coverage with Evidence Development - Experiences from selected countries	published	24	2009	<a href="http://eprints.hta.lbg.ac.at/818/">http://eprints.hta.lbg.ac.at/818/</a>
Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study.	published	25	2010	<a href="http://eprints.hta.lbg.ac.at/900/">http://eprints.hta.lbg.ac.at/900/</a>
Developing a decision aid on HPV-vaccination for young girls and women/ mothers	published	26	2009	<a href="http://www.hpv-entscheidungshilfe.de/">http://www.hpv-entscheidungshilfe.de/</a>
Evaluations of child and adolescent psychiatry. (Part 1a) - Theory and practice about measurement dimensions, indicators and instruments.	published	27	2009	<a href="http://eprints.hta.lbg.ac.at/846/">http://eprints.hta.lbg.ac.at/846/</a>
Child and adolescent psychiatry. (Part 1b) - A systematic review of health economic evaluations	published	28	2009	<a href="http://eprints.hta.lbg.ac.at/862/">http://eprints.hta.lbg.ac.at/862/</a>
Child and adolescent psychiatry. (Part 2) - Evaluation study at the University Department of Child and Adolescent Psychiatry (Christian-Doppler-Klinik) in Salzburg	ongoing	40		
Telemedicine in Stroke Management. Systematic Review.	published	29	2009	<a href="http://eprints.hta.lbg.ac.at/844/">http://eprints.hta.lbg.ac.at/844/</a>
Tocolysis in preterm labour - A systematic review of evidence-based guidelines, effectiveness and health economic evaluations	published	30	2009	<a href="http://eprints.hta.lbg.ac.at/825/">http://eprints.hta.lbg.ac.at/825/</a>
Outpatient cardiac rehabilitation. Part 3a: Retrospective cohort study (with/without phase III rehabilitation - Explorative analysis and developing of an evaluation plan	published	31a	2010	<a href="http://eprints.hta.lbg.ac.at/875/">http://eprints.hta.lbg.ac.at/875/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Outpatient cardiac rehabilitation. Part 3b: Retrospective cohort study (with/without phase III rehabilitation - Application of the evaluation plan	published	31b	2010	<a href="http://eprints.hta.lbg.ac.at/876/">http://eprints.hta.lbg.ac.at/876/</a>
Horizon scanning in oncology - Part 2: From pilot to routine	ongoing	32		<a href="#">siehe HSS Publikationen ganz unten</a>
Artificial food colours and Hyperactivity	published	34	2009	<a href="http://eprints.hta.lbg.ac.at/848/">http://eprints.hta.lbg.ac.at/848/</a>
Status quo Mammography screening. Evaluation results from organised programs	published	35	2009	<a href="http://eprints.hta.lbg.ac.at/863/">http://eprints.hta.lbg.ac.at/863/</a>
Evaluation of diagnostic technologies – background, challenges, methods	published	36	2010	<a href="http://eprints.hta.lbg.ac.at/898/">http://eprints.hta.lbg.ac.at/898/</a>
Impact from HTA-research for the Austrian health care system. Part 1: Overview - Update	published	37a	2010	<a href="http://eprints.hta.lbg.ac.at/877/">http://eprints.hta.lbg.ac.at/877/</a>
Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey	published	37b	2011	<a href="http://eprints.hta.lbg.ac.at/907/">http://eprints.hta.lbg.ac.at/907/</a>
Acquisition Processes of Certain Product Groups in Hospitals - Orthopaedic and Cardiac Implants	published	38	2009	<a href="http://eprints.hta.lbg.ac.at/864/">http://eprints.hta.lbg.ac.at/864/</a>
Haemocompletan® P and Fibrogammin® P in acquired hypofibrinogenemia	published	39	2009	<a href="http://eprints.hta.lbg.ac.at/870/">http://eprints.hta.lbg.ac.at/870/</a>
Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design	published	41a	2010	<a href="http://eprints.hta.lbg.ac.at/873/">http://eprints.hta.lbg.ac.at/873/</a>
Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs	published	41b	2010	<a href="http://eprints.hta.lbg.ac.at/874/">http://eprints.hta.lbg.ac.at/874/</a>
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Principles of standardised work in HTA (WP1.2)	published	44a	2011	<a href="http://eprints.hta.lbg.ac.at/932/">http://eprints.hta.lbg.ac.at/932/</a>
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Glossary of terms (WP2.1)	finished	44b	2011	not published
Reorientation of the Austrian parent-child preventive care programme. Part 1: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood	published	45a	2011	<a href="http://eprints.hta.lbg.ac.at/912/">http://eprints.hta.lbg.ac.at/912/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 2: International Policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry	published	45b	2011	<a href="http://eprints.hta.lbg.ac.at/913/">http://eprints.hta.lbg.ac.at/913/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 3: Status quo of the financing and cost structures of parent-child services in Austria	published	45c	2011	<a href="http://eprints.hta.lbg.ac.at/914/">http://eprints.hta.lbg.ac.at/914/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 4: Synthesis of Parts 1-3, Recommendations	published	45d	2011	<a href="http://eprints.hta.lbg.ac.at/915/">http://eprints.hta.lbg.ac.at/915/</a>
Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications	published	47	2010	<a href="http://eprints.hta.lbg.ac.at/901/">http://eprints.hta.lbg.ac.at/901/</a>
Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research	published	48	2011	<a href="http://eprints.hta.lbg.ac.at/908/">http://eprints.hta.lbg.ac.at/908/</a>
Quality of care in oncology and its measurement	published	49a	2011	<a href="http://eprints.hta.lbg.ac.at/934/">http://eprints.hta.lbg.ac.at/934/</a>
Generic indicators for process quality in oncological care. A compendium	published	49b	2012	<a href="http://eprints.hta.lbg.ac.at/946/">http://eprints.hta.lbg.ac.at/946/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 5: Preterm birth	published	50	2012	<a href="http://eprints.hta.lbg.ac.at/939/">http://eprints.hta.lbg.ac.at/939/</a>
Systematic review of the efficacy and safety of treatments for varicose veins of the lower extremity	published	51	2011	<a href="http://eprints.hta.lbg.ac.at/930/">http://eprints.hta.lbg.ac.at/930/</a>
Appraisal of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment-regimens with dasatinib, imatinib or nilotinib	published	52	2012	<a href="http://eprints.hta.lbg.ac.at/953/">http://eprints.hta.lbg.ac.at/953/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 6: Health visiting services in the international context and implementation options for Austria	published	53	2012	<a href="http://eprints.hta.lbg.ac.at/947/">http://eprints.hta.lbg.ac.at/947/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 7: Options for an electronic implementation	published	54	2012	<a href="http://eprints.hta.lbg.ac.at/948/">http://eprints.hta.lbg.ac.at/948/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 8: Budget Impact Analysis	published	55	2012	<a href="http://eprints.hta.lbg.ac.at/949/">http://eprints.hta.lbg.ac.at/949/</a>
Occupational therapy in Austria	published	56	2012	<a href="http://eprints.hta.lbg.ac.at/972/">http://eprints.hta.lbg.ac.at/972/</a>
Disinvestment. Overview of disinvestment experiences and challenges in selected countries.	published	57	2011	<a href="http://eprints.hta.lbg.ac.at/926/">http://eprints.hta.lbg.ac.at/926/</a>
Standards on how to parameterise models via published literature - Input of the LBI HTA for IFEDH workpackage 4	published	58	2012	<a href="http://eprints.hta.lbg.ac.at/990/">http://eprints.hta.lbg.ac.at/990/</a>
Occupational therapy Part 3 – Occupational therapy for patients after stroke	published	59	2012	<a href="http://eprints.hta.lbg.ac.at/973/">http://eprints.hta.lbg.ac.at/973/</a>
Occupational Therapy Part 4 for Dementia and Part V for Depression	published	60	2012	<a href="http://eprints.hta.lbg.ac.at/974/">http://eprints.hta.lbg.ac.at/974/</a>
Horizon Scanning in Oncology - Impact Evaluation	published	61	2012	<a href="http://eprints.hta.lbg.ac.at/969/">http://eprints.hta.lbg.ac.at/969/</a>
Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	62	2013	<a href="http://eprints.hta.lbg.ac.at/996/">http://eprints.hta.lbg.ac.at/996/</a>
(III) Health and access to health care in homeless people: A literature review	published	63	2012	<a href="http://eprints.hta.lbg.ac.at/980/">http://eprints.hta.lbg.ac.at/980/</a>
Day Surgery: A Systematic Overview	published	64	2012	<a href="http://eprints.hta.lbg.ac.at/987/">http://eprints.hta.lbg.ac.at/987/</a>
Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition)	published	41a	2012	<a href="http://eprints.hta.lbg.ac.at/981/">http://eprints.hta.lbg.ac.at/981/</a>
Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition)	published	41b	2012	<a href="http://eprints.hta.lbg.ac.at/982/">http://eprints.hta.lbg.ac.at/982/</a>
Screening for Colorectal Cancer. Part 3: update von Teil 1 (41 a) und Teil 2 (41 b), Quality of screening colonoscopy	published	41c	2013	<a href="http://eprints.hta.lbg.ac.at/983/">http://eprints.hta.lbg.ac.at/983/</a>
Marketing Authorisations under Exceptional Circumstances for Oncology Drugs	published	65	2013	<a href="http://eprints.hta.lbg.ac.at/992/">http://eprints.hta.lbg.ac.at/992/</a>
Outpatient cardiac rehabilitation; Part 6: Scientific monitoring of the "Multi-centre, prospective cohort study with two control groups (with/without phase III)"	ongoing	66		

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
„Mental Health“ rehabilitation for children and adolescents – A literature overview on indications, outcomes and evaluation instruments	published	67	2013	<a href="http://eprints.hta.lbg.ac.at/1012/">http://eprints.hta.lbg.ac.at/1012/</a>
Identifying ineffective interventions and health technologies: models and their implementation	published	68	2013	<a href="http://eprints.hta.lbg.ac.at/1014/">http://eprints.hta.lbg.ac.at/1014/</a>
Treatment by clinical psychologists. Part 1: Overview of training requirements and systematic stakeholder analysis on delineation of areas of responsibility and treatment methods.	published	69a	2013	<a href="http://eprints.hta.lbg.ac.at/1018/">http://eprints.hta.lbg.ac.at/1018/</a>
Treatment by clinical psychologists. Part 2: Literature overview on methods of treatment and areas of application.	published	69b	2013	<a href="http://eprints.hta.lbg.ac.at/1019/">http://eprints.hta.lbg.ac.at/1019/</a>
Occupational therapy in children. Part 1 – Literature review on indications, utilisation and recommendations	published	70	2013	<a href="http://eprints.hta.lbg.ac.at/1016/">http://eprints.hta.lbg.ac.at/1016/</a>
Cost- and Budget-Impact-Analysis of an Increase in Day Surgery for Selected Indications	published	71	2014	<a href="http://eprints.hta.lbg.ac.at/1035/">http://eprints.hta.lbg.ac.at/1035/</a>
p16/KI-67 Dual Stain in cytological screening of cervical cancer: A systematic literature review of clinical studies based on a review of methodological approaches for assessing biomarkers	published	72	2013	<a href="http://eprints.hta.lbg.ac.at/1009/">http://eprints.hta.lbg.ac.at/1009/</a>
Evidence requirements for the authorisation and reimbursement of high risk medical devices in USA, Australi and Canada	published	73	2013	<a href="http://eprints.hta.lbg.ac.at/1017/">http://eprints.hta.lbg.ac.at/1017/</a>
Proton- and Carbon Ion therapy	published	74	2013	<a href="http://eprints.hta.lbg.ac.at/1021/">http://eprints.hta.lbg.ac.at/1021/</a>
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review	published	75	2014	<a href="http://eprints.hta.lbg.ac.at/1025/">http://eprints.hta.lbg.ac.at/1025/</a>
Positron emission tomography/ Computer tomography (PET/ CT): need-assessment for planning	published	77	2015	<a href="http://eprints.hta.lbg.ac.at/1045/">http://eprints.hta.lbg.ac.at/1045/</a>
Acupuncture - areas of application, current evidence and proven indications	published	78	2014	<a href="http://eprints.hta.lbg.ac.at/1042/">http://eprints.hta.lbg.ac.at/1042/</a>
Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids	published	79	2014	<a href="http://eprints.hta.lbg.ac.at/1047/">http://eprints.hta.lbg.ac.at/1047/</a>
Criteria and recommendations for an adequate use of Magnetic Resonance Imaging (MRI)	published	80	2014	<a href="http://eprints.hta.lbg.ac.at/1043/">http://eprints.hta.lbg.ac.at/1043/</a>
Lithuania: HTA Training	finished	81	2015	not published
Adequacy of MRI 2	finished	82		not published
Effects of (im)material incentives on health behaviour, Part I: Definitions, theories and models and Part II: Overview of reviews covering 4 health issues	published	83	2015	<a href="http://eprints.hta.lbg.ac.at/1078/">http://eprints.hta.lbg.ac.at/1078/</a>
Robotic Surgery	published	84	2015	<a href="http://eprints.hta.lbg.ac.at/1077/">http://eprints.hta.lbg.ac.at/1077/</a>
Endovascular stroke therapy	finished	85		not published
Patient- and citizen participation in HTA processes - Good Practice	published	86	2016	<a href="http://eprints.hta.lbg.ac.at/1088/">http://eprints.hta.lbg.ac.at/1088/</a>
Nudging -Behavioral Sciences applied to the Big Four Public Health issues	published	83/ Addendum	2015	<a href="http://eprints.hta.lbg.ac.at/1078/">http://eprints.hta.lbg.ac.at/1078/</a>
Mechanical thrombectomy in acute ischemic stroke. Patient characteristics, structural requirements and (differential) diagnosis	published	87	2016	<a href="http://eprints.hta.lbg.ac.at/1084/">http://eprints.hta.lbg.ac.at/1084/</a>
New concept for primary care (Supply mandates)	published	88	2016	<a href="http://eprints.hta.lbg.ac.at/1110/">http://eprints.hta.lbg.ac.at/1110/</a>
Outpatient cardiac rehabilitation, Part 6: Economic evaluation	published	89	2016	<a href="http://eprints.hta.lbg.ac.at/1102/">http://eprints.hta.lbg.ac.at/1102/</a>
Options to identify inappropriate use of MRI, Part 3	published	80c	2015	<a href="http://eprints.hta.lbg.ac.at/1159/">http://eprints.hta.lbg.ac.at/1159/</a>
Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2	published	80b	2015	<a href="http://eprints.hta.lbg.ac.at/1090/">http://eprints.hta.lbg.ac.at/1090/</a>
Outpatient cardiac rehabilitation, Part 6: Scientific monitoring of the Multi-centre, prospective cohort study with two control groups (with/without phase III)	published	90	2016	<a href="http://eprints.hta.lbg.ac.at/1101/">http://eprints.hta.lbg.ac.at/1101/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 12: Economic evaluation of selected screenings during pregnancy	published	91	2017	<a href="http://eprints.hta.lbg.ac.at/1112/">http://eprints.hta.lbg.ac.at/1112/</a>
Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	62/Update 2016	2016	<a href="http://eprints.hta.lbg.ac.at/996/">http://eprints.hta.lbg.ac.at/996/</a>
Re-orientation of the Austrian parent-child preventive care programme. Part 11: Screening recommendations of the expert working group for pregnancy	published	92	2019	<a href="http://eprints.hta.lbg.ac.at/1163/">http://eprints.hta.lbg.ac.at/1163/</a>
Legally recognized psychotherapy methods in Austria – effect factors, indications, setting specific aspects	published	93	2017	<a href="http://eprints.hta.lbg.ac.at/1143/">http://eprints.hta.lbg.ac.at/1143/</a>
Telekardiologie - Map Ö and evaluation methods: Work in Progress	finished	94	2017	not published
Transcatheter Aortic Valve Implantation Part 1: A systematic review of economic evaluations	published	95a	2017	<a href="http://eprints.hta.lbg.ac.at/1139/">http://eprints.hta.lbg.ac.at/1139/</a>
Social Return on Investment' for Child and Adolescence Health: Outcomes, Methods and Economic Parameters	published	96	2017	<a href="http://eprints.hta.lbg.ac.at/1142/">http://eprints.hta.lbg.ac.at/1142/</a>
Perinatal Care at the threshold of viability. Part I Resource planning for Neonatal Care Units: clinical outcomes and resource needs	published	97a	2018	<a href="http://eprints.hta.lbg.ac.at/1146/">http://eprints.hta.lbg.ac.at/1146/</a>
Part II (Good) Practice Models to handle Ethical, Organizational, and Social Challenges	published	97b	2018	<a href="http://eprints.hta.lbg.ac.at/1148/">http://eprints.hta.lbg.ac.at/1148/</a>
Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)	published	97b	2018	<a href="http://eprints.hta.lbg.ac.at/1148/">http://eprints.hta.lbg.ac.at/1148/</a>
Transthoracic Echocardiography (TAVI) Part 1: Use in Austria and Guideline Recommendations for Appropriate Use	published	98		<a href="http://eprints.hta.lbg.ac.at/1158/">http://eprints.hta.lbg.ac.at/1158/</a>
Transcatheter Aortic Valve Implantation (TAVI) Part 2: Frequency, Patient Collective, and Geographic Variation Over Time in Austria	published	95b	2017	<a href="http://eprints.hta.lbg.ac.at/1141/">http://eprints.hta.lbg.ac.at/1141/</a>
PET/PET-CT Evidence for need based planning in Germany and Austria	published	77/Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1178/">http://eprints.hta.lbg.ac.at/1178/</a>
'Dropouts in psychotherapies – Theoretical reflections and counter-strategies	published	100	2018	<a href="http://eprints.hta.lbg.ac.at/1157/">http://eprints.hta.lbg.ac.at/1157/</a>
Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications	published	101	2018	<a href="http://eprints.hta.lbg.ac.at/1174/">http://eprints.hta.lbg.ac.at/1174/</a>
Genexpressionstest Mammaprint® zur Entscheidungs-unterstützung für/gegen adjuvante Chemotherapie bei primärem Brustkrebs	published	102	2018	<a href="http://eprints.hta.lbg.ac.at/1147/">http://eprints.hta.lbg.ac.at/1147/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Screening of fetal trisomes 21, 18 and 13 by noninvasive prenatal testing	published	103	2018	<a href="http://eprints.hta.lbg.ac.at/1153/">http://eprints.hta.lbg.ac.at/1153/</a>
Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety	published	105	2018	<a href="http://eprints.hta.lbg.ac.at/1182/">http://eprints.hta.lbg.ac.at/1182/</a>
Screening programmes for children and adolescents aged 6-14 years in selected countries and recommendations from evidence-based guidelines	published	106	2018	<a href="http://eprints.hta.lbg.ac.at/1212/">http://eprints.hta.lbg.ac.at/1212/</a>
Stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible (electroporation Nanoknife®) for localised prostate cancer (PCa): a systematic review	published	107	2018	<a href="http://eprints.hta.lbg.ac.at/1165">http://eprints.hta.lbg.ac.at/1165</a>
Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery	published	108	2019	<a href="http://eprints.hta.lbg.ac.at/1198/">http://eprints.hta.lbg.ac.at/1198/</a>
Pricing and reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process taking into account international experience	published	109	2019	<a href="http://eprints.hta.lbg.ac.at/1183/">http://eprints.hta.lbg.ac.at/1183/</a>
EditTechnology Forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption	published	111		<a href="http://eprints.hta.lbg.ac.at/1197/">http://eprints.hta.lbg.ac.at/1197/</a>
Natalizumab as treatment for Multiple Sclerosis: a systematic review	published	112	2019	<a href="http://eprints.hta.lbg.ac.at/1190/">http://eprints.hta.lbg.ac.at/1190/</a>
Uptake of mental health care benefits (co-) funded by the Tyrolean health insurance (Village)	published	113a	2019	<a href="http://eprints.hta.lbg.ac.at/1180/">http://eprints.hta.lbg.ac.at/1180/</a>
Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance	published	113b	2019	<a href="http://eprints.hta.lbg.ac.at/1181/">http://eprints.hta.lbg.ac.at/1181/</a>
Evaluation methods for benefit assessment of easily accessible outpatient health centres for vulnerable groups - Focus: homeless and uninsured persons	published	114	2019	<a href="http://eprints.hta.lbg.ac.at/1195/">http://eprints.hta.lbg.ac.at/1195/</a>
Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate surgical risk TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)	published	115	2019	<a href="http://eprints.hta.lbg.ac.at/1188/">http://eprints.hta.lbg.ac.at/1188/</a>
C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report	published	116	2019	<a href="http://eprints.hta.lbg.ac.at/1194/">http://eprints.hta.lbg.ac.at/1194/</a>
3D-Druck von maßgefertigten oder individualisierbaren Implantaten und Schnittschablonen: EUnetHTA-Report	published	117	2019	<a href="http://eprints.hta.lbg.ac.at/1209/">http://eprints.hta.lbg.ac.at/1209/</a>
Screening for Diabetes mellitus: guideline recommendations	published	118	2019	<a href="http://eprints.hta.lbg.ac.at/1213/">http://eprints.hta.lbg.ac.at/1213/</a>
Irreversible Elektroporation (IRE) bei Bauchspeicheldrüsen- und Leberkrebs. EUnetHTA-Report	published	119	2019	<a href="http://eprints.hta.lbg.ac.at/1211/">http://eprints.hta.lbg.ac.at/1211/</a>
Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies	published	120	2019	<a href="http://eprints.hta.lbg.ac.at/1214/">http://eprints.hta.lbg.ac.at/1214/</a>
Prevention of cervical cancer in Austria – Implementation of HPV testing into the existing screening programme	published	121	2019	<a href="http://eprints.hta.lbg.ac.at/1223/">http://eprints.hta.lbg.ac.at/1223/</a>
Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies	published	122	2019	<a href="http://eprints.hta.lbg.ac.at/1222">http://eprints.hta.lbg.ac.at/1222</a>
Screening programmes for children and adolescents aged 6-18 years, Part II	finished	123		not published
POCT/ Point of Care Tests: D-Dimer und Troponin	published	124	2019	<a href="http://eprints.hta.lbg.ac.at/1224/">http://eprints.hta.lbg.ac.at/1224/</a>
Minimum volume standards for quality assurance in day surgery	published	125	2019	<a href="http://eprints.hta.lbg.ac.at/1225/">http://eprints.hta.lbg.ac.at/1225/</a>
Health Services Research in Oncology: Patients with Non-small Cell Lung Cancer (NSCLC) treated with Anti-PD1/PD-L1 Therapy in Real-World Practice	published	126	2020	<a href="https://eprints.aihta.at/1227">https://eprints.aihta.at/1227</a>
Health Services Research in Oncology Part I: End-of-Life Care	published	127	2020	<a href="http://eprints.aihta.at/1233">http://eprints.aihta.at/1233</a>
Robotics and functional electrical stimulation for stroke rehabilitation	published	128	2020	<a href="https://eprints.aihta.at/1302">https://eprints.aihta.at/1302</a>
Home treatment in child and adolescent psychiatry: An analysis of effectiveness and integrated care	published	129	2020	<a href="http://eprints.aihta.at/1275/">http://eprints.aihta.at/1275/</a>
Molecular genetic diagnostics as a triage mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)	published	130	2020	<a href="http://eprints.aihta.at/1281/">http://eprints.aihta.at/1281/</a>
Minimally invasive surgical procedures for the treatment of benign prostatic hyperplasia (BPH)	ongoing	131	2020	
Lung cancer screening in risk groups. Systematic review(s) of effectiveness and utility (part 1)	published	132a	2020	<a href="http://eprints.aihta.at/1282/">http://eprints.aihta.at/1282/</a>
Lung cancer screening in risk groups. Systematic review(s) of Costs and budgetary consequences (part 2)	published	132b	2020	<a href="https://eprints.aihta.at/1283">https://eprints.aihta.at/1283</a>
Effectiveness of music therapy	published	133	2020	<a href="http://eprints.aihta.at/1280/">http://eprints.aihta.at/1280/</a>
Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples	published	134	2020	<a href="https://eprints.aihta.at/1279">https://eprints.aihta.at/1279</a>
Epidemiology of long COVID: a preliminary report. German short version of the original KCE report	published	135a	2021	<a href="https://eprints.aihta.at/1321">https://eprints.aihta.at/1321</a>
Long COVID care pathways: a systematic review	published	135b	2021	<a href="https://eprints.aihta.at/1342">https://eprints.aihta.at/1342</a>
Evidence-based reimbursement processes in Europe Part 1: Reimbursement decisions for medical procedures in Austria. An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit catalogue	ongoing	136		
Evidence-based reimbursement processes in Europe Part 2: A comparative analysis of selected medical devices in German and Austrian hospitals and possible influencing factors	ongoing	137		
(Good) practice organizational models using real-world evidence for public funding of high prized therapies	published	138	2021	<a href="https://eprints.aihta.at/1329">https://eprints.aihta.at/1329</a>
Effectiveness of national strategies for non-communicable diseases.	ongoing	139		
Contrasting evidence from pivotal trials with real world evidence for treatment with nivolumab in malignant melanoma.	published	140	2021	<a href="https://eprints.aihta.at/1341">https://eprints.aihta.at/1341</a>
Process and evaluation of digital health applications in the context of "Symptom Checkers"	published	141	2021	<a href="https://eprints.aihta.at/1348/">https://eprints.aihta.at/1348/</a>
The economic and social dimension of parental mental illness	ongoing	142		

Title	Status	No.	Year	Download/Link
<b>Rapid Assessments</b>				
Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy	published	1	2006	<a href="http://eprints.hta.lbg.ac.at/34/">http://eprints.hta.lbg.ac.at/34/</a>
Avastin® for age-related macular degeneration	published	2	2007	<a href="http://eprints.hta.lbg.ac.at/718/">http://eprints.hta.lbg.ac.at/718/</a>
Rational Vaccination Policies - decision support. Review of International Literature for "Rational" Vaccination Policies	published	3	2008	<a href="http://eprints.hta.lbg.ac.at/761/">http://eprints.hta.lbg.ac.at/761/</a>
Sacral Nerve Stimulation for Fecal Incontinence	published	4	2011	<a href="http://eprints.hta.lbg.ac.at/925/">http://eprints.hta.lbg.ac.at/925/</a>
Avastin® for age-related macular degeneration: Gutachten zu Stand des Wissens	published	5	2012	<a href="http://eprints.hta.lbg.ac.at/989/">http://eprints.hta.lbg.ac.at/989/</a>
Hybrid-Operation rooms	published	6	2013	<a href="http://eprints.hta.lbg.ac.at/995/">http://eprints.hta.lbg.ac.at/995/</a>
Transparency: continuing medical education and NIS database	published	7a	2015	<a href="http://eprints.hta.lbg.ac.at/1053/">http://eprints.hta.lbg.ac.at/1053/</a>
Transparency: continuing medical education	published	7b	2015	<a href="http://eprints.hta.lbg.ac.at/1072/">http://eprints.hta.lbg.ac.at/1072/</a>
Transparency: continuing medical education/observational study and NIS database	published	7c	2016	<a href="http://eprints.hta.lbg.ac.at/1080/">http://eprints.hta.lbg.ac.at/1080/</a>
Pharma: Disclosure of transfers of value in austria 2015	published	7d	2017	<a href="http://eprints.hta.lbg.ac.at/1107/">http://eprints.hta.lbg.ac.at/1107/</a>
Drugs in Oncology: an overview of benefit and refund practices in Europe	published	8	2016	<a href="http://eprints.hta.lbg.ac.at/1091/">http://eprints.hta.lbg.ac.at/1091/</a>
HTAs on Medical Devices and Procedures in Europe: Timing, Risk-Classes, Product-Groups, Assessments	published	12	2016	<a href="http://eprints.hta.lbg.ac.at/1108/">http://eprints.hta.lbg.ac.at/1108/</a>
Importance and transparency of non-interventional drug studies (NIS) in selected countries: A comparison with Austria	published	7c/1. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1122/">http://eprints.hta.lbg.ac.at/1122/</a>
Sponsoring of Patient initiatives in Austria 2015. Update of the Systematic Analysis 2014	published	7b/1. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1125/">http://eprints.hta.lbg.ac.at/1125/</a>
Sponsoring of Patient initiatives in Austria 2016. Update of the Systematic Analysis 2015 and 2014	published	7b/2. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1132/">http://eprints.hta.lbg.ac.at/1132/</a>
MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EunethHTA report	published	13	2018	<a href="http://eprints.hta.lbg.ac.at/1147/">http://eprints.hta.lbg.ac.at/1147/</a>
FoundationOne®CDx: Bestimmung von genetischen Profilen solider Tumore	published	14	2019	<a href="http://eprints.hta.lbg.ac.at/1215/">http://eprints.hta.lbg.ac.at/1215/</a>
Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016	published	7b/3. Update 2017	2019	<a href="http://eprints.hta.lbg.ac.at/1217/">http://eprints.hta.lbg.ac.at/1217/</a>
Pharma: Disclosure of transfers of value in austria 2018. Update of the systematic analysis 2015	published	7d/1. Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1218/">http://eprints.hta.lbg.ac.at/1218/</a>
<b>Policy Briefs</b>				
Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre	published	1	2020	<a href="http://eprints.aihta.at/1228/">http://eprints.aihta.at/1228/</a>
Covid-19: HSS/ Horizon Scanning Living Document (Part 1 & Part 2)	published	2	2020	<a href="http://eprints.aihta.at/1234/">http://eprints.aihta.at/1234/</a>
PET-Indikationen	published	3	2020	<a href="http://eprints.aihta.at/1249/">http://eprints.aihta.at/1249/</a>
Update: Proton- and Carbon Ion therapy	published	4	2020	<a href="http://eprints.aihta.at/1245/">http://eprints.aihta.at/1245/</a>
Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence – recommendations from evidence-based guidelines	published	5	2021	<a href="http://eprints.aihta.at/1303/">http://eprints.aihta.at/1303/</a>
Car-T Cell Therapies	published	6a	2020	<a href="http://eprints.aihta.at/1268/">http://eprints.aihta.at/1268/</a>
ATMPs and Gene Therapies	published	6b	2020	<a href="http://eprints.aihta.at/1269/">http://eprints.aihta.at/1269/</a>
Transparency: Sponsoring of patient initiatives, Update	published	7	2021	<a href="https://eprints.aihta.at/1308/">https://eprints.aihta.at/1308/</a>
Combinationtherapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of covid-19	published	8	2021	<a href="http://eprints.aihta.at/1313/">http://eprints.aihta.at/1313/</a>
Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19	published	9	2021	<a href="http://eprints.aihta.at/1314/">http://eprints.aihta.at/1314/</a>
Nicht-Interventionelle Studien (NIS) in Österreich	published	10	2021	<a href="https://eprints.aihta.at/1333/">https://eprints.aihta.at/1333/</a>
Stool DNA testing for colorectal cancer (CRC) screening	published	11	2021	<a href="https://eprints.aihta.at/1335/">https://eprints.aihta.at/1335/</a>
<b>Decision Support Documents</b>				
Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia	published	1	2007	<a href="http://eprints.hta.lbg.ac.at/747/">http://eprints.hta.lbg.ac.at/747/</a>
Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors	published	2	2007	<a href="http://eprints.hta.lbg.ac.at/749/">http://eprints.hta.lbg.ac.at/749/</a>
Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract	published	3	2007	<a href="http://eprints.hta.lbg.ac.at/51/">http://eprints.hta.lbg.ac.at/51/</a>
New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review	published	6	2008	<a href="http://eprints.hta.lbg.ac.at/763/">http://eprints.hta.lbg.ac.at/763/</a>
LDL apheresis. Systematic review	published	7	2008	<a href="http://eprints.hta.lbg.ac.at/764/">http://eprints.hta.lbg.ac.at/764/</a>
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8	2008	<a href="http://eprints.hta.lbg.ac.at/770/">http://eprints.hta.lbg.ac.at/770/</a>
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review	published	10	2008	<a href="http://eprints.hta.lbg.ac.at/768/">http://eprints.hta.lbg.ac.at/768/</a>
Selective Cell Apheresis in Inflammatory Bowel Disease	published	11	2008	<a href="http://eprints.hta.lbg.ac.at/792/">http://eprints.hta.lbg.ac.at/792/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review	published	12	2008	<a href="http://eprints.hta.lbg.ac.at/758/">http://eprints.hta.lbg.ac.at/758/</a>
Optical Coherence Tomography. Systematic review	published	13	2008	<a href="http://eprints.hta.lbg.ac.at/84/">http://eprints.hta.lbg.ac.at/84/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14	2008	<a href="http://eprints.hta.lbg.ac.at/762/">http://eprints.hta.lbg.ac.at/762/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15	2008	<a href="http://eprints.hta.lbg.ac.at/769/">http://eprints.hta.lbg.ac.at/769/</a>
Aromatherapy for pain relief and psychological problems. Systematic review	published	16	2008	<a href="http://eprints.hta.lbg.ac.at/765/">http://eprints.hta.lbg.ac.at/765/</a>
Bach Flower Remedies for pain relief and psychological problems. Systematic review	published	17	2008	<a href="http://eprints.hta.lbg.ac.at/767/">http://eprints.hta.lbg.ac.at/767/</a>
Percutaneous aortic valve replacement. Systematic review	published	18	2008	<a href="http://eprints.hta.lbg.ac.at/766/">http://eprints.hta.lbg.ac.at/766/</a>
Enzyme Replacement Therapy for Lysosomal Storage Diseases	published	19	2008	<a href="http://eprints.hta.lbg.ac.at/812/">http://eprints.hta.lbg.ac.at/812/</a>
Endobronchial valve implantation for emphysema	finished	20	2008	not published
Chemoneurolysis and intradiscal electrotherapy (IDET). Systematic Review.	published	21a	2009	<a href="http://eprints.hta.lbg.ac.at/828/">http://eprints.hta.lbg.ac.at/828/</a>
Percutaneous nucleotomy and percutaneous laser disk decompression. Systematic Review.	published	21b	2009	<a href="http://eprints.hta.lbg.ac.at/830/">http://eprints.hta.lbg.ac.at/830/</a>
Injection therapies and radiofrequency for the treatment of chronic back pain. Systematic Review.	published	22	2009	<a href="http://eprints.hta.lbg.ac.at/831/">http://eprints.hta.lbg.ac.at/831/</a>
Intraoperative radiotherapy for primary breast cancer. Systematic Review.	published	23	2009	<a href="http://eprints.hta.lbg.ac.at/832/">http://eprints.hta.lbg.ac.at/832/</a>
Drug coated balloon catheter. Systematic Review.	published	24	2009	<a href="http://eprints.hta.lbg.ac.at/833/">http://eprints.hta.lbg.ac.at/833/</a>
Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review.	published	25	2009	<a href="http://eprints.hta.lbg.ac.at/834/">http://eprints.hta.lbg.ac.at/834/</a>
Image guided radiotherapy using cone-beam computed tomography. Systematic Review.	published	26	2009	<a href="http://eprints.hta.lbg.ac.at/835/">http://eprints.hta.lbg.ac.at/835/</a>
Pumpless extracorporeal lung assist (PECLA). Systematic Review.	published	27	2009	<a href="http://eprints.hta.lbg.ac.at/836/">http://eprints.hta.lbg.ac.at/836/</a>
Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review.	published	30	2009	<a href="http://eprints.hta.lbg.ac.at/837/">http://eprints.hta.lbg.ac.at/837/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/895/">http://eprints.hta.lbg.ac.at/895/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/896/">http://eprints.hta.lbg.ac.at/896/</a>
Percutaneous aortic valve replacement. Systematic review	published	18/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/897/">http://eprints.hta.lbg.ac.at/897/</a>
Endobronchial valve implantation for emphysema. Systematic review	finished	20/ Update 2009	2009	not published
Bioresonance for allergies, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases.	published	31	2009	<a href="http://eprints.hta.lbg.ac.at/842/">http://eprints.hta.lbg.ac.at/842/</a>
Colon Hydrotherapy for defecation disorders. Systematic Review	published	32	2009	<a href="http://eprints.hta.lbg.ac.at/827/">http://eprints.hta.lbg.ac.at/827/</a>
International comparison of antenatal care in pregnant women	published	33	2009	<a href="http://eprints.hta.lbg.ac.at/826/">http://eprints.hta.lbg.ac.at/826/</a>
Autologous Chondrocyte Implantation	published	34	2009	<a href="http://eprints.hta.lbg.ac.at/865/">http://eprints.hta.lbg.ac.at/865/</a>
New influenza (swine flu) – data & facts for decision support.	published	35	2009	<a href="http://eprints.hta.lbg.ac.at/845/">http://eprints.hta.lbg.ac.at/845/</a>
Hyperthermia	published	36	2010	<a href="http://eprints.hta.lbg.ac.at/883/">http://eprints.hta.lbg.ac.at/883/</a>
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37	2010	<a href="http://eprints.hta.lbg.ac.at/887/">http://eprints.hta.lbg.ac.at/887/</a>
Artificial disc replacement	published	38	2010	<a href="http://eprints.hta.lbg.ac.at/886/">http://eprints.hta.lbg.ac.at/886/</a>
Laser angioplasty of coronary arteries	published	39	2010	<a href="http://eprints.hta.lbg.ac.at/885/">http://eprints.hta.lbg.ac.at/885/</a>
Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors	published	40	2010	<a href="http://eprints.hta.lbg.ac.at/889/">http://eprints.hta.lbg.ac.at/889/</a>
Mitral valve repair using a mitral clip	published	41	2010	<a href="http://eprints.hta.lbg.ac.at/888/">http://eprints.hta.lbg.ac.at/888/</a>
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/890/">http://eprints.hta.lbg.ac.at/890/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/892/">http://eprints.hta.lbg.ac.at/892/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/893/">http://eprints.hta.lbg.ac.at/893/</a>
Percutaneous aortic valve replacement. Systematic review	published	18/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/894/">http://eprints.hta.lbg.ac.at/894/</a>
Endobronchial valve implantation for emphysema. Systematic review	published	20/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/891/">http://eprints.hta.lbg.ac.at/891/</a>
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. German version.	published	43	2011	<a href="http://eprints.hta.lbg.ac.at/916/">http://eprints.hta.lbg.ac.at/916/</a>
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. English version.	published	43	2011	<a href="http://eprints.hta.lbg.ac.at/917/">http://eprints.hta.lbg.ac.at/917/</a>
Percutaneous Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	44	2011	<a href="http://eprints.hta.lbg.ac.at/918/">http://eprints.hta.lbg.ac.at/918/</a>
Renal denervation in patients with essential hypertension	published	45	2011	<a href="http://eprints.hta.lbg.ac.at/919/">http://eprints.hta.lbg.ac.at/919/</a>
Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke	published	46	2011	<a href="http://eprints.hta.lbg.ac.at/920/">http://eprints.hta.lbg.ac.at/920/</a>



## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. German version.	published	47	2011	<a href="http://eprints.hta.lbg.ac.at/921/">http://eprints.hta.lbg.ac.at/921/</a>
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. English version.	published	47	2011	<a href="http://eprints.hta.lbg.ac.at/922/">http://eprints.hta.lbg.ac.at/922/</a>
Percutaneous aortic valve replacement with a side note to hybrid operating rooms	published	18/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/923/">http://eprints.hta.lbg.ac.at/923/</a>
Outpatient cardiac rehabilitation. Part 4: Options for carrying out a prospective study	published	48	2011	<a href="http://eprints.hta.lbg.ac.at/928/">http://eprints.hta.lbg.ac.at/928/</a>
Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases	published	49	2011	<a href="http://eprints.hta.lbg.ac.at/933/">http://eprints.hta.lbg.ac.at/933/</a>
Outpatient cardiac rehabilitation Part 5: Preparation of the study protocol for the planned prospective study	published	50	2012	<a href="http://eprints.hta.lbg.ac.at/971/">http://eprints.hta.lbg.ac.at/971/</a>
Training therapy in physical medicine – Systematic Review	published	51	2012	<a href="http://eprints.hta.lbg.ac.at/950/">http://eprints.hta.lbg.ac.at/950/</a>
Exercise therapy (Krankengymnastik/ Heilgymnastik) in physical medicine	published	52	2012	<a href="http://eprints.hta.lbg.ac.at/951/">http://eprints.hta.lbg.ac.at/951/</a>
Radiofrequency ablation of tumors of the lung and mediastinal lymph nodes	published	53	2012	<a href="http://eprints.hta.lbg.ac.at/957/">http://eprints.hta.lbg.ac.at/957/</a>
Radiofrequency ablation of bone tumors (osteoid-osteoma and osseus metastases)	published	54	2012	<a href="http://eprints.hta.lbg.ac.at/958/">http://eprints.hta.lbg.ac.at/958/</a>
Radiofrequency ablation of head and neck cancer	published	55	2012	<a href="http://eprints.hta.lbg.ac.at/959/">http://eprints.hta.lbg.ac.at/959/</a>
Radiofrequency ablation of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland)	published	56	2012	<a href="http://eprints.hta.lbg.ac.at/960/">http://eprints.hta.lbg.ac.at/960/</a>
Radiofrequency ablation of breast cancer	published	57	2012	<a href="http://eprints.hta.lbg.ac.at/961/">http://eprints.hta.lbg.ac.at/961/</a>
Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)	published	58	2012	<a href="http://eprints.hta.lbg.ac.at/962/">http://eprints.hta.lbg.ac.at/962/</a>
Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)	published	59	2012	<a href="http://eprints.hta.lbg.ac.at/963/">http://eprints.hta.lbg.ac.at/963/</a>
Sling suspension in male urinary incontinence	published	60	2012	<a href="http://eprints.hta.lbg.ac.at/964/">http://eprints.hta.lbg.ac.at/964/</a>
Stem cell therapy for urinary stress incontinence	published	6/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/965/">http://eprints.hta.lbg.ac.at/965/</a>
Mitral valve repair using a mitral clip	published	41/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/967/">http://eprints.hta.lbg.ac.at/967/</a>
Intraoperative radiotherapy for primary breast cancer. Systematic Review.	published	23/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/966/">http://eprints.hta.lbg.ac.at/966/</a>
Renal denervation in patients with essential hypertension	published	45/update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/968/">http://eprints.hta.lbg.ac.at/968/</a>
HIV testing in healthy subjects: an international comparison Austria	published	61	2012	<a href="http://eprints.hta.lbg.ac.at/979/">http://eprints.hta.lbg.ac.at/979/</a>
Extracorporeal shock wave therapy (ESWT) of non-union or delayed union of fractures	published	62	2012	<a href="http://eprints.hta.lbg.ac.at/975/">http://eprints.hta.lbg.ac.at/975/</a>
Hyperthermia	published	36/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/986/">http://eprints.hta.lbg.ac.at/986/</a>
Evidence overview of therapeutic hypothermia	published	63	2012	<a href="http://eprints.hta.lbg.ac.at/985/">http://eprints.hta.lbg.ac.at/985/</a>
Percutaneous coronary intervention for chronic total occlusion	published	64	2013	<a href="http://eprints.hta.lbg.ac.at/1000/">http://eprints.hta.lbg.ac.at/1000/</a>
Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)	published	65	2013	<a href="http://eprints.hta.lbg.ac.at/1001/">http://eprints.hta.lbg.ac.at/1001/</a>
Repair of cartilage defects via matrix-associated autologous chondrocyte immigration	published	66	2013	<a href="http://eprints.hta.lbg.ac.at/1002/">http://eprints.hta.lbg.ac.at/1002/</a>
Duodeno-jejunal bypass liner (DJBL) for patients with obesity	published	67	2013	<a href="http://eprints.hta.lbg.ac.at/1008/">http://eprints.hta.lbg.ac.at/1008/</a>
Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)	published	68	2013	<a href="http://eprints.hta.lbg.ac.at/1003/">http://eprints.hta.lbg.ac.at/1003/</a>
Endovascular repair of aortic aneurysms	published	69	2013	<a href="http://eprints.hta.lbg.ac.at/1004/">http://eprints.hta.lbg.ac.at/1004/</a>
Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks	published	70	2013	<a href="http://eprints.hta.lbg.ac.at/1005/">http://eprints.hta.lbg.ac.at/1005/</a>
Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)	published	71	2013	<a href="http://eprints.hta.lbg.ac.at/1006/">http://eprints.hta.lbg.ac.at/1006/</a>
Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB) (1st Update)	published	24/Update 2013	2013	<a href="http://eprints.hta.lbg.ac.at/1007/">http://eprints.hta.lbg.ac.at/1007/</a>
Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations	published	72	2014	<a href="http://eprints.hta.lbg.ac.at/1036/">http://eprints.hta.lbg.ac.at/1036/</a>
Zostavax® for prevention of Herpes Zoster	published	73	2013	<a href="http://eprints.hta.lbg.ac.at/1013/">http://eprints.hta.lbg.ac.at/1013/</a>
Hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinosis	published	74	2014	<a href="http://eprints.hta.lbg.ac.at/1031/">http://eprints.hta.lbg.ac.at/1031/</a>
Percutaneous transluminal angioplasty (PTA) with drug-eluting stents	published	75	2014	<a href="http://eprints.hta.lbg.ac.at/1032/">http://eprints.hta.lbg.ac.at/1032/</a>
Endobronchial valves in emphysema	published	20/Update 2014	2014	<a href="http://eprints.hta.lbg.ac.at/1028/">http://eprints.hta.lbg.ac.at/1028/</a>
Percutaneous left atrial appendage closure	published	44/Update 2014	2014	<a href="http://eprints.hta.lbg.ac.at/1029/">http://eprints.hta.lbg.ac.at/1029/</a>
Stereotactic Radiofrequency Ablation (SRFA) in hepatocellular carcinoma	published	76	2014	<a href="http://eprints.hta.lbg.ac.at/1030/">http://eprints.hta.lbg.ac.at/1030/</a>
Biomarker guidance	published	77	2014	<a href="http://eprints.hta.lbg.ac.at/1041/">http://eprints.hta.lbg.ac.at/1041/</a>
Re-orientation of the Austrian parent-child preventive care programme Part 10: further development of the mother-child-pass. Scientific support of the appraisal process	published	78	2014	<a href="http://eprints.hta.lbg.ac.at/1039/">http://eprints.hta.lbg.ac.at/1039/</a>

Title	Status	No.	Year	Download/Link
Vaccination against Human Papillomavirus (HPV). Decision Support for adolescent girls and women/ mothers	finished	79	2014	not published
Outpatient cardiac rehabilitation. Part 6a: Multi-centre, prospective cohort study with two control groups (with/without phase III). Baseline characteristics.	finished	80	2014	not published
Fully bioresorbable scaffolds for coronary artery disease: Systematic Review	published	81	2015	<a href="http://eprints.hta.lbg.ac.at/1060/">http://eprints.hta.lbg.ac.at/1060/</a>
Transcatheter mitral valve-in-valve implantation (TMViVI)	published	82	2015	<a href="http://eprints.hta.lbg.ac.at/1058/">http://eprints.hta.lbg.ac.at/1058/</a>
Endovascular embolisation of intracranial aneurysms with Flow Diverter	published	83	2015	<a href="http://eprints.hta.lbg.ac.at/1054/">http://eprints.hta.lbg.ac.at/1054/</a>
Defibrotide for hepatic veno-occlusive disease	published	84	2015	<a href="http://eprints.hta.lbg.ac.at/1061/">http://eprints.hta.lbg.ac.at/1061/</a>
Intracorneal ring segments for keratoconus	published	85	2015	<a href="http://eprints.hta.lbg.ac.at/1055/">http://eprints.hta.lbg.ac.at/1055/</a>
Neurostimulation for cluster headache	published	86	2015	<a href="http://eprints.hta.lbg.ac.at/1062/">http://eprints.hta.lbg.ac.at/1062/</a>
Local injection therapy with bulking agents for faecal incontinence	published	87	2015	<a href="http://eprints.hta.lbg.ac.at/1059/">http://eprints.hta.lbg.ac.at/1059/</a>
Percutaneous left atrial appendage closure (2.Update 2015)	published	44/Update 2015	2015	<a href="http://eprints.hta.lbg.ac.at/1056/">http://eprints.hta.lbg.ac.at/1056/</a>
Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1.Update 2015)	published	68/Update 2015	2015	<a href="http://eprints.hta.lbg.ac.at/1057/">http://eprints.hta.lbg.ac.at/1057/</a>
Hadron therapy in children. Evidence synthesis to 15 pediatric tumors	published	88	2015	<a href="http://eprints.hta.lbg.ac.at/1049/">http://eprints.hta.lbg.ac.at/1049/</a>
Biodegradable stents for the treatment of refractory or recurrent benign oesophageal Stenosis: German summary to EUnetHTA-report	published	89	2015	<a href="http://eprints.hta.lbg.ac.at/1067/">http://eprints.hta.lbg.ac.at/1067/</a>
Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices	published	90	2015	<a href="http://eprints.hta.lbg.ac.at/1063/">http://eprints.hta.lbg.ac.at/1063/</a>
HTA Strategy for Lithuania	published	90a	2015	<a href="http://eprints.hta.lbg.ac.at/1064/">http://eprints.hta.lbg.ac.at/1064/</a>
Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction: German summary to EUnetHTA-report	published	91	2015	<a href="http://eprints.hta.lbg.ac.at/1073/">http://eprints.hta.lbg.ac.at/1073/</a>
Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review.	published	92	2015	<a href="http://eprints.hta.lbg.ac.at/1071/">http://eprints.hta.lbg.ac.at/1071/</a>
Percutaneous mitral repair with chronic mitral insufficiency (Mitraclip®, Carillon®, NeoChord DS1000) . German Executive summary of the same EUnetHTA report	published	93	2015	<a href="http://eprints.hta.lbg.ac.at/1075/">http://eprints.hta.lbg.ac.at/1075/</a>
Mechanical thrombectomy in acute ischemic stroke. German Executive summary of the same report EUnetHTA	published	94	2016	<a href="http://eprints.hta.lbg.ac.at/1081/">http://eprints.hta.lbg.ac.at/1081/</a>
Screening, diagnostic testing and therapeutic indication for occupational therapy in children and adolescents with Developmental Coordination Disorder	published	96	2016	<a href="http://eprints.hta.lbg.ac.at/1092/">http://eprints.hta.lbg.ac.at/1092/</a>
Leadless pacemakers for right ventricle pacing	published	97	2016	<a href="http://eprints.hta.lbg.ac.at/1094/">http://eprints.hta.lbg.ac.at/1094/</a>
Autologous matrix-induced chondrogenesis for cartilage repair	published	98	2016	<a href="http://eprints.hta.lbg.ac.at/1095/">http://eprints.hta.lbg.ac.at/1095/</a>
Radiofrequency denervation for low back pain	published	99	2016	<a href="http://eprints.hta.lbg.ac.at/1096/">http://eprints.hta.lbg.ac.at/1096/</a>
Hypoglossal nerve stimulation for obstructive sleep apnoe	published	100	2016	<a href="http://eprints.hta.lbg.ac.at/1097/">http://eprints.hta.lbg.ac.at/1097/</a>
Magnetic esophageal ring for gastroesophageal reflux disease	published	101	2016	<a href="http://eprints.hta.lbg.ac.at/1098/">http://eprints.hta.lbg.ac.at/1098/</a>
Percutaneous transluminal coronary angioplasty with drug-eluting balloon	published	24/ Update 2016	2016	<a href="http://eprints.hta.lbg.ac.at/1093/">http://eprints.hta.lbg.ac.at/1093/</a>
Hepatitis C virus screening in hospitals	published	102	2016	<a href="http://eprints.hta.lbg.ac.at/1103/">http://eprints.hta.lbg.ac.at/1103/</a>
Portable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac arrest	published	103	2016	<a href="http://eprints.hta.lbg.ac.at/1109/">http://eprints.hta.lbg.ac.at/1109/</a>
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)	published	104	2017	<a href="http://eprints.hta.lbg.ac.at/1128/">http://eprints.hta.lbg.ac.at/1128</a>
Prostate artery embolisation for benign prostatic hyperplasia	published	105	2017	<a href="http://eprints.hta.lbg.ac.at/1118/">http://eprints.hta.lbg.ac.at/1118</a>
Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS	published	106	2017	<a href="http://eprints.hta.lbg.ac.at/1129/">http://eprints.hta.lbg.ac.at/1129</a>
Repetitive transcranial magnetic stimulation for treatment-resistant major depression	published	107	2017	<a href="http://eprints.hta.lbg.ac.at/1130/">http://eprints.hta.lbg.ac.at/1130</a>
Radiofrequency ablation for metastatic spinal lesions	published	108	2017	<a href="http://eprints.hta.lbg.ac.at/1131/">http://eprints.hta.lbg.ac.at/1131</a>
Percutaneous disc volume reduction with focus on chemonucleolysis	published	21 /Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1126/">http://eprints.hta.lbg.ac.at/1126</a>
Leadless pacemakers for right ventricle pacing	published	97/Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1127/">http://eprints.hta.lbg.ac.at/1127</a>
Endobronchial valve implantation for emphysema	published	20//4.Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1166/">http://eprints.hta.lbg.ac.at/1166</a>
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37/1. Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1167/">http://eprints.hta.lbg.ac.at/1167</a>
Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	44/3. Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1168/">http://eprints.hta.lbg.ac.at/1168</a>
Subcutaneous implantable cardioverter defibrillator (ICD)	published	109	2018	<a href="http://eprints.hta.lbg.ac.at/1169/">http://eprints.hta.lbg.ac.at/1169</a>
Lymphovenous anastomoses in patients with primary and secondary lymphedema	published	110	2018	<a href="http://eprints.hta.lbg.ac.at/1170/">http://eprints.hta.lbg.ac.at/1170</a>
Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas	published	111	2018	<a href="http://eprints.hta.lbg.ac.at/1171/">http://eprints.hta.lbg.ac.at/1171</a>
Meniscal allograft transplantation	published	112	2018	<a href="http://eprints.hta.lbg.ac.at/1172/">http://eprints.hta.lbg.ac.at/1172</a>
Baroreceptor activation therapy for treatment-resistant hypertension	published	113	2018	<a href="http://eprints.hta.lbg.ac.at/1173/">http://eprints.hta.lbg.ac.at/1173</a>



Title	Status	No.	Year	Download/Link
External stimulation of the trigeminal nerve for the prevention and treatment of episodic and chronic migraine (Cefaly)	published	114	2018	<a href="http://eprints.hta.lbg.ac.at/1177/">http://eprints.hta.lbg.ac.at/1177/</a>
Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk - Update 2018	published	103/Update 2018	2019	<a href="http://eprints.hta.lbg.ac.at/1186">http://eprints.hta.lbg.ac.at/1186</a>
Osteochondral Allograft Transplantation (knee or other joints)	published	115	2019	<a href="http://eprints.hta.lbg.ac.at/1173">http://eprints.hta.lbg.ac.at/1173</a>
Allograft for anterior and posterior cruciate ligament reconstruction	published	116	2019	<a href="http://eprints.hta.lbg.ac.at/1177/">http://eprints.hta.lbg.ac.at/1177/</a>
Human dermal allograft for reconstruction of rotator cuff tears	published	117	2019	<a href="http://eprints.hta.lbg.ac.at/1186">http://eprints.hta.lbg.ac.at/1186</a>
Lu-177-labeled Prostata-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant metastatic Prostata Cancer	published	118	2019	<a href="http://eprints.hta.lbg.ac.at/1204">http://eprints.hta.lbg.ac.at/1204</a>
Radiofrequency denervation for lumbar and cervical facet joint pain	published	99/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1205">http://eprints.hta.lbg.ac.at/1205</a>
(Single-step) scaffold-based cartilage repair in the knee	published	98/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1206">http://eprints.hta.lbg.ac.at/1206</a>
Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)	published	65/ Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1207">http://eprints.hta.lbg.ac.at/1207</a>
Implantation of a completely bioresorbable stent into the coronary vessels	published	81/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1200">http://eprints.hta.lbg.ac.at/1200</a>
Upper airway stimulation for moderate-to-severe sleep apnea	published	100/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1201">http://eprints.hta.lbg.ac.at/1201</a>
Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report	published	81/1.Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1201">http://eprints.hta.lbg.ac.at/1201</a>
Telemonitoring and pulmonanry artery pressure-guided treatment of heart failure	published	119	2020	<a href="http://eprints.aihta.at/1254">http://eprints.aihta.at/1254</a>
Ultrasound-guided transcervical Radiofrequency ablation of Myoma	published	120	2020	<a href="http://eprints.aihta.at/1255">http://eprints.aihta.at/1255</a>
Leadless Pacemakers for Right Ventricle Pacing	published	97/Update 2019	2020	<a href="http://eprints.aihta.at/1252">http://eprints.aihta.at/1252</a>
Extracorporeal cytokine headsorption	published	106/Update 2019	2020	<a href="http://eprints.aihta.at/1253">http://eprints.aihta.at/1253</a>
Percutaneous transvascular implantation of a coronary sinus constricting stent	published	121	2020	<a href="http://eprints.aihta.at/1256">http://eprints.aihta.at/1256</a>
Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer	published	122	2020	<a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>
Photodynamic therapy in prostate cancer with padeliporfin (TOOKAD)	published	123	2020	<a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>
ercutaneous left ventricular assist devices: micro-axial flow pumps	published	124	2021	<a href="https://eprints.aihta.at/1323">https://eprints.aihta.at/1323</a>
Liposuction for surgical therapy of lipoedema	published	125	2021	<a href="https://eprints.aihta.at/1324">https://eprints.aihta.at/1324</a>
Triphasic biomaterial for augmentation of the osteoporotic femoral neck	published	126	2021	<a href="https://eprints.aihta.at/1325">https://eprints.aihta.at/1325</a>
Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD)	published	127	2021	<a href="https://eprints.aihta.at/1326">https://eprints.aihta.at/1326</a>
Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses	published	128	2021	<a href="https://eprints.aihta.at/1327">https://eprints.aihta.at/1327</a>
Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia	published	129	2021	<a href="https://eprints.aihta.at/1328">https://eprints.aihta.at/1328</a>
Implantation of Bulking Agents for Faecal Incontinence (1st Update)	published	87/1. Update	2021	<a href="https://eprints.aihta.at/1322">https://eprints.aihta.at/1322</a>
<b>Decision Support Documents: Horizon Scaning in Oncology</b>				
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes	published	1	2009	<a href="http://eprints.hta.lbg.ac.at/852/">http://eprints.hta.lbg.ac.at/852/</a>
Cetuximab (Erbix®) in EGFR-expressing Non-Small Cell Lung Cancer	published	2	2009	<a href="http://eprints.hta.lbg.ac.at/856/">http://eprints.hta.lbg.ac.at/856/</a>
Everolimus (Afinitor®) for advanced/metastatic kidney cancer	published	3	2009	<a href="http://eprints.hta.lbg.ac.at/857/">http://eprints.hta.lbg.ac.at/857/</a>
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia	published	4	2009	<a href="http://eprints.hta.lbg.ac.at/860/">http://eprints.hta.lbg.ac.at/860/</a>
Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma	published	5	2009	<a href="http://eprints.hta.lbg.ac.at/861/">http://eprints.hta.lbg.ac.at/861/</a>
Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer	published	6	2010	<a href="http://eprints.hta.lbg.ac.at/868/">http://eprints.hta.lbg.ac.at/868/</a>
Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer	published	7	2010	<a href="http://eprints.hta.lbg.ac.at/869/">http://eprints.hta.lbg.ac.at/869/</a>
Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma	published	8	2010	<a href="http://eprints.hta.lbg.ac.at/878/">http://eprints.hta.lbg.ac.at/878/</a>
Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer	published	9	2010	<a href="http://eprints.hta.lbg.ac.at/882/">http://eprints.hta.lbg.ac.at/882/</a>
Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma	published	10	2010	<a href="http://eprints.hta.lbg.ac.at/884/">http://eprints.hta.lbg.ac.at/884/</a>
Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer	published	11	2010	<a href="http://eprints.hta.lbg.ac.at/880/">http://eprints.hta.lbg.ac.at/880/</a>
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer	published	12	2010	<a href="http://eprints.hta.lbg.ac.at/881/">http://eprints.hta.lbg.ac.at/881/</a>
Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma	published	13	2010	<a href="http://eprints.hta.lbg.ac.at/902/">http://eprints.hta.lbg.ac.at/902/</a>
Iplimumab for pre-treated patients with advanced/metastatic melanoma	published	14	2011	<a href="http://eprints.hta.lbg.ac.at/905/">http://eprints.hta.lbg.ac.at/905/</a>
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase	published	15	2011	<a href="http://eprints.hta.lbg.ac.at/906/">http://eprints.hta.lbg.ac.at/906/</a>
Cabazitaxel (Jevtana®) for the second-line therapy of patients with hormone-refractory metastatic prostate cancer	published	16	2011	<a href="http://eprints.hta.lbg.ac.at/911/">http://eprints.hta.lbg.ac.at/911/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Dasatinib (Sprycel®) for the first-line therapy of patients with newly diagnosed chronic phase philadelphia chromosome positive chronic myeloid leukemia	published	17	2011	<a href="http://eprints.hta.lbg.ac.at/910/">http://eprints.hta.lbg.ac.at/910/</a>
Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer	published	18	2011	<a href="http://eprints.hta.lbg.ac.at/927/">http://eprints.hta.lbg.ac.at/927/</a>
S-1 (Teysuno) in chemotherapy-naive patients with advanced NSCLC.	published	19	2011	<a href="http://eprints.hta.lbg.ac.at/931/">http://eprints.hta.lbg.ac.at/931/</a>
Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy	published	20	2011	<a href="http://eprints.hta.lbg.ac.at/938/">http://eprints.hta.lbg.ac.at/938/</a>
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011	published	6/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/935/">http://eprints.hta.lbg.ac.at/935/</a>
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011	published	4/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/937/">http://eprints.hta.lbg.ac.at/937/</a>
Panitumumab (Vectibix®) as 1st line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011	published	11/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/936/">http://eprints.hta.lbg.ac.at/936/</a>
Axitinib for 2nd-line metastatic renal cell carcinoma	published	21	2012	<a href="http://eprints.hta.lbg.ac.at/945/">http://eprints.hta.lbg.ac.at/945/</a>
Erlotinib for the 1st -line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations	published	22	2012	<a href="http://eprints.hta.lbg.ac.at/941/">http://eprints.hta.lbg.ac.at/941/</a>
Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma	published	23	2012	<a href="http://eprints.hta.lbg.ac.at/940/">http://eprints.hta.lbg.ac.at/940/</a>
Everolimus for advanced pancreatic neuroendocrine tumours	published	24	2012	<a href="http://eprints.hta.lbg.ac.at/942/">http://eprints.hta.lbg.ac.at/942/</a>
Romidepsin for the treatment of peripheral t-cell lymphoma	published	25	2012	<a href="http://eprints.hta.lbg.ac.at/956/">http://eprints.hta.lbg.ac.at/956/</a>
Brentuximab vedotin for the treatment of Hodgkin Lymphoma and systemic anaplastic large cell lymphoma	published	26	2012	<a href="http://eprints.hta.lbg.ac.at/955/">http://eprints.hta.lbg.ac.at/955/</a>
Bevacizumab in combination with chemotherapy regimens for previously treated HER2-negative metastatic breast cancer	published	27	2012	<a href="http://eprints.hta.lbg.ac.at/952/">http://eprints.hta.lbg.ac.at/952/</a>
Lenalidomide for the treatment of myelodysplastic syndromes	published	28	2012	<a href="http://eprints.hta.lbg.ac.at/954/">http://eprints.hta.lbg.ac.at/954/</a>
Bortezomib for the treatment of multiple myeloma in a transplant setting	published	29	2012	<a href="http://eprints.hta.lbg.ac.at/976/">http://eprints.hta.lbg.ac.at/976/</a>
Ipilimumab for the first-line therapy of advanced/metastatic melanoma	published	30	2012	<a href="http://eprints.hta.lbg.ac.at/970/">http://eprints.hta.lbg.ac.at/970/</a>
Pertuzumab for the first-line therapy of metastatic HER2 positive breast cancer	published	31	2012	<a href="http://eprints.hta.lbg.ac.at/978/">http://eprints.hta.lbg.ac.at/978/</a>
Everolimus for the treatment of breast cancer	published	32	2012	<a href="http://eprints.hta.lbg.ac.at/977/">http://eprints.hta.lbg.ac.at/977/</a>
Lenalidomide for the first-line therapy of multiple myeloma	published	33	2012	<a href="http://eprints.hta.lbg.ac.at/984/">http://eprints.hta.lbg.ac.at/984/</a>
Trametinib for advanced or metastatic BRAF V600E mutation-positive melanoma	published	34	2012	<a href="http://eprints.hta.lbg.ac.at/988/">http://eprints.hta.lbg.ac.at/988/</a>
Crizotinib, PF-01231066 (Xalkor®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC).	published	35	2012	<a href="http://eprints.hta.lbg.ac.at/993/">http://eprints.hta.lbg.ac.at/993/</a>
Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer	published	36	2013	<a href="http://eprints.hta.lbg.ac.at/998/">http://eprints.hta.lbg.ac.at/998/</a>
Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy	published	37	2013	<a href="http://eprints.hta.lbg.ac.at/997/">http://eprints.hta.lbg.ac.at/997/</a>
Aflibercept (Zaltrap®) in addition to FOLFIRI for the treatment of metastatic colorectal cancer	published	38	2013	<a href="http://eprints.hta.lbg.ac.at/999/">http://eprints.hta.lbg.ac.at/999/</a>
Pomalidomide (Pomalyst®) in combination with low-dose dexamethasone vs. high-dose dexamethasone in subjects with refractory multiple myeloma or relapsed and refractory multiple myeloma	published	39	2013	<a href="http://eprints.hta.lbg.ac.at/1010/">http://eprints.hta.lbg.ac.at/1010/</a>
Regorafenib (Stivarga®) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy	published	40	2013	<a href="http://eprints.hta.lbg.ac.at/1011/">http://eprints.hta.lbg.ac.at/1011/</a>
Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)	published	41	2013	<a href="http://eprints.hta.lbg.ac.at/1020/">http://eprints.hta.lbg.ac.at/1020/</a>
Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma	published	42	2013	<a href="http://eprints.hta.lbg.ac.at/1015/">http://eprints.hta.lbg.ac.at/1015/</a>
Nab-Paclitaxel (Abraxane®, Ebetaxel®) as first-line therapy for metastatic adenocarcinoma of the pancreas	published	43	2014	<a href="http://eprints.hta.lbg.ac.at/1023/">http://eprints.hta.lbg.ac.at/1023/</a>
Radium-223 Dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease	published	44	2014	<a href="http://eprints.hta.lbg.ac.at/1024/">http://eprints.hta.lbg.ac.at/1024/</a>
Obinutuzumab afutuzumab (Gazyva®) as first line therapy for chronic lymphocytic leukaemia (CLL)	published	45	2014	<a href="http://eprints.hta.lbg.ac.at/1027/">http://eprints.hta.lbg.ac.at/1027/</a>
Bevacizumab (Avastin®) as maintenance therapy for patients with advanced colorectal carcinoma	published	46	2014	<a href="http://eprints.hta.lbg.ac.at/1034/">http://eprints.hta.lbg.ac.at/1034/</a>
Ibrutinib, PCI-32765 (Imbruvica®) for relapsed or refractory CLL	published	47	2014	<a href="http://eprints.hta.lbg.ac.at/1037/">http://eprints.hta.lbg.ac.at/1037/</a>
Bevacizumab (Avastin®) for platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer	published	48	2014	<a href="http://eprints.hta.lbg.ac.at/1038/">http://eprints.hta.lbg.ac.at/1038/</a>
Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia	published	49	2014	<a href="http://eprints.hta.lbg.ac.at/1044/">http://eprints.hta.lbg.ac.at/1044/</a>
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma	published	50	2015	<a href="http://eprints.hta.lbg.ac.at/1051/">http://eprints.hta.lbg.ac.at/1051/</a>
Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy	published	51	2015	<a href="http://eprints.hta.lbg.ac.at/1066/">http://eprints.hta.lbg.ac.at/1066/</a>
Carfilzomib (Kyprolis®) in patients with relapsed multiple myeloma who have received one to three prior lines of therapy	published	52	2015	<a href="http://eprints.hta.lbg.ac.at/1070/">http://eprints.hta.lbg.ac.at/1070/</a>
Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer	published	53	2015	<a href="http://eprints.hta.lbg.ac.at/1068/">http://eprints.hta.lbg.ac.at/1068/</a>
Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma	published	54	2015	<a href="http://eprints.hta.lbg.ac.at/1069/">http://eprints.hta.lbg.ac.at/1069/</a>

Title	Status	No.	Year	Download/Link
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma	published	55	2015	<a href="http://eprints.hta.lbg.ac.at/1076/">http://eprints.hta.lbg.ac.at/1076/</a>
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer	published	56	2016	<a href="http://eprints.hta.lbg.ac.at/1082/">http://eprints.hta.lbg.ac.at/1082/</a>
Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)	published	57	2016	<a href="http://eprints.hta.lbg.ac.at/1085/">http://eprints.hta.lbg.ac.at/1085/</a>
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)	published	58	2016	<a href="http://eprints.hta.lbg.ac.at/1086/">http://eprints.hta.lbg.ac.at/1086/</a>
Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy	published	59	2016	<a href="http://eprints.hta.lbg.ac.at/1089/">http://eprints.hta.lbg.ac.at/1089/</a>
Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)	published	60	2016	<a href="http://eprints.hta.lbg.ac.at/1022/">http://eprints.hta.lbg.ac.at/1022/</a>
Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma	published	61	2016	<a href="http://eprints.hta.lbg.ac.at/1048/">http://eprints.hta.lbg.ac.at/1048/</a>
Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion	published	62	2016	<a href="http://eprints.hta.lbg.ac.at/1083/">http://eprints.hta.lbg.ac.at/1083/</a>
Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	63	2016	<a href="http://eprints.hta.lbg.ac.at/1111/">http://eprints.hta.lbg.ac.at/1111/</a>
Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer	published	64	2017	<a href="http://eprints.hta.lbg.ac.at/1114/">http://eprints.hta.lbg.ac.at/1114/</a>
Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer	published	65	2017	<a href="http://eprints.hta.lbg.ac.at/1115/">http://eprints.hta.lbg.ac.at/1115/</a>
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy	published	66	2017	<a href="http://eprints.hta.lbg.ac.at/1116/">http://eprints.hta.lbg.ac.at/1116/</a>
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma	published	67	2017	<a href="http://eprints.hta.lbg.ac.at/1119/">http://eprints.hta.lbg.ac.at/1119/</a>
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)	published	68	2017	<a href="http://eprints.hta.lbg.ac.at/1120/">http://eprints.hta.lbg.ac.at/1120/</a>
Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer	published	69	2017	<a href="http://eprints.hta.lbg.ac.at/1123/">http://eprints.hta.lbg.ac.at/1123/</a>
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)	published	70	2017	<a href="http://eprints.hta.lbg.ac.at/1124/">http://eprints.hta.lbg.ac.at/1124/</a>
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer	published	71	2017	<a href="http://eprints.hta.lbg.ac.at/1136/">http://eprints.hta.lbg.ac.at/1136/</a>
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)	published	72	2017	<a href="http://eprints.hta.lbg.ac.at/1137/">http://eprints.hta.lbg.ac.at/1137/</a>
Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA report	published	73	2017	<a href="http://eprints.hta.lbg.ac.at/1138/">http://eprints.hta.lbg.ac.at/1138/</a>
Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia	published	74	2017	<a href="http://eprints.hta.lbg.ac.at/1140/">http://eprints.hta.lbg.ac.at/1140/</a>
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)	published	75	2017	<a href="http://eprints.hta.lbg.ac.at/1144/">http://eprints.hta.lbg.ac.at/1144/</a>
Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy	published	76	2017	<a href="http://eprints.hta.lbg.ac.at/1145/">http://eprints.hta.lbg.ac.at/1145/</a>
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)	published	77	2018	<a href="http://eprints.hta.lbg.ac.at/1152/">http://eprints.hta.lbg.ac.at/1152/</a>
Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)	published	78	2018	<a href="http://eprints.hta.lbg.ac.at/1154/">http://eprints.hta.lbg.ac.at/1154/</a>
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)	published	79	2018	<a href="http://eprints.hta.lbg.ac.at/1155/">http://eprints.hta.lbg.ac.at/1155/</a>
Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC)	published	80	2018	<a href="http://eprints.hta.lbg.ac.at/1160/">http://eprints.hta.lbg.ac.at/1160/</a>
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma	published	81	2018	<a href="http://eprints.hta.lbg.ac.at/1161/">http://eprints.hta.lbg.ac.at/1161/</a>
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC	published	82	2018	<a href="http://eprints.hta.lbg.ac.at/1175/">http://eprints.hta.lbg.ac.at/1175/</a>
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)	published	83	2018	<a href="http://eprints.hta.lbg.ac.at/1176/">http://eprints.hta.lbg.ac.at/1176/</a>
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)	published	84	2018	<a href="http://eprints.hta.lbg.ac.at/1184/">http://eprints.hta.lbg.ac.at/1184/</a>
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström's macroglobulinemia	published	85	2018	<a href="http://eprints.hta.lbg.ac.at/1185/">http://eprints.hta.lbg.ac.at/1185/</a>
Olaparib (Lynparza®) für die Erstlinien-Erhaltungstherapie von Patientinnen mit neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom	published	86	2019	<a href="http://eprints.hta.lbg.ac.at/1192/">http://eprints.hta.lbg.ac.at/1192/</a>
Atezolizumab (Tecentriq®) und Nab-Paclitaxel (Abraxane®) für die Behandlung von Patientinnen mit fortgeschrittenem, triple-negativem Mammakarzinom (aTNBC)	published	87	2019	<a href="http://eprints.hta.lbg.ac.at/1193/">http://eprints.hta.lbg.ac.at/1193/</a>
Darolutamide für die Behandlung von Patienten mit nichtmetastasiertem, kastrationsresistentem Prostatakarzinom	published	88	2019	<a href="http://eprints.hta.lbg.ac.at/1199/">http://eprints.hta.lbg.ac.at/1199/</a>
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)	published	89	2019	<a href="http://eprints.hta.lbg.ac.at/1210/">http://eprints.hta.lbg.ac.at/1210/</a>
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)	published	90	2019	<a href="http://eprints.hta.lbg.ac.at/1216/">http://eprints.hta.lbg.ac.at/1216/</a>
Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)	published	91	2019	<a href="http://eprints.hta.lbg.ac.at/1219/">http://eprints.hta.lbg.ac.at/1219/</a>
<b>Decision Support Documents: Oncology Fact Scheets</b>				
Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions	published	1	2020	<a href="http://eprints.aihta.at/1229/">http://eprints.aihta.at/1229/</a>
Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)	published	2	2020	<a href="http://eprints.aihta.at/1230/">http://eprints.aihta.at/1230/</a>
Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL	published	3	2020	<a href="http://eprints.aihta.at/1231/">http://eprints.aihta.at/1231/</a>
Brigatinib (Alunbrig®) in ALK-positive non-small-cell lung cancer (NSCLC)	published	4	2020	<a href="http://eprints.aihta.at/1232/">http://eprints.aihta.at/1232/</a>
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)	published	5	2020	<a href="http://eprints.aihta.at/1235/">http://eprints.aihta.at/1235/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)	published	6	2020	<a href="http://eprints.aihta.at/1236/">http://eprints.aihta.at/1236/</a>
Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation	published	7	2020	<a href="http://eprints.aihta.at/1240/">http://eprints.aihta.at/1240/</a>
Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen	published	8	2020	<a href="http://eprints.aihta.at/1241/">http://eprints.aihta.at/1241/</a>
Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma	published	9	2020	<a href="http://eprints.aihta.at/1242/">http://eprints.aihta.at/1242/</a>
Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)	published	10	2020	<a href="http://eprints.aihta.at/1243/">http://eprints.aihta.at/1243/</a>
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer	published	11	2020	<a href="http://eprints.aihta.at/1246/">http://eprints.aihta.at/1246/</a>
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor-positive advanced breast cancer	published	12	2020	<a href="http://eprints.aihta.at/1247/">http://eprints.aihta.at/1247/</a>
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC	published	13	2020	<a href="http://eprints.aihta.at/1248/">http://eprints.aihta.at/1248/</a>
Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphomas (NHL)	published	14	2020	<a href="https://eprints.aihta.at/1261/">https://eprints.aihta.at/1261/</a>
Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)	published	15	2020	<a href="https://eprints.aihta.at/1263/">https://eprints.aihta.at/1263/</a>
Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)	published	16	2020	<a href="https://eprints.aihta.at/1264/">https://eprints.aihta.at/1264/</a>
Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)	published	17	2020	<a href="https://eprints.aihta.at/1265/">https://eprints.aihta.at/1265/</a>
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	published	18	2020	<a href="https://eprints.aihta.at/1266/">https://eprints.aihta.at/1266/</a>
Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)	published	19	2020	<a href="https://eprints.aihta.at/1267/">https://eprints.aihta.at/1267/</a>
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)	published	20	2020	<a href="https://eprints.aihta.at/1270/">https://eprints.aihta.at/1270/</a>
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)	published	21	2020	<a href="https://eprints.aihta.at/1271/">https://eprints.aihta.at/1271/</a>
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer	published	22	2020	<a href="https://eprints.aihta.at/1272/">https://eprints.aihta.at/1272/</a>
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)	published	23	2020	<a href="https://eprints.aihta.at/1273/">https://eprints.aihta.at/1273/</a>
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer	published	24	2020	<a href="https://eprints.aihta.at/1274/">https://eprints.aihta.at/1274/</a>
Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)	published	25	2020	<a href="https://eprints.aihta.at/1276/">https://eprints.aihta.at/1276/</a>
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)	published	26	2020	<a href="https://eprints.aihta.at/1277/">https://eprints.aihta.at/1277/</a>
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)	published	27	2020	<a href="https://eprints.aihta.at/1278/">https://eprints.aihta.at/1278/</a>
Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)	published	28	2020	<a href="https://eprints.aihta.at/1284/">https://eprints.aihta.at/1284/</a>
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)	published	29	2020	<a href="https://eprints.aihta.at/1285/">https://eprints.aihta.at/1285/</a>
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo™) for the treatment of early and metastatic breast cancer	published	30	2020	<a href="https://eprints.aihta.at/1286/">https://eprints.aihta.at/1286/</a>
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma	published	31	2020	<a href="https://eprints.aihta.at/1287/">https://eprints.aihta.at/1287/</a>
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer	published	32	2021	<a href="https://eprints.aihta.at/1288/">https://eprints.aihta.at/1288/</a>
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis	published	33	2020	<a href="https://eprints.aihta.at/1289/">https://eprints.aihta.at/1289/</a>
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer	published	34	2021	<a href="https://eprints.aihta.at/1290/">https://eprints.aihta.at/1290/</a>
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)	published	35	2021	<a href="https://eprints.aihta.at/1291/">https://eprints.aihta.at/1291/</a>
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer	published	36	2021	<a href="https://eprints.aihta.at/1292/">https://eprints.aihta.at/1292/</a>
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer	published	37	2021	<a href="https://eprints.aihta.at/1293/">https://eprints.aihta.at/1293/</a>
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)	published	38	2021	<a href="https://eprints.aihta.at/1296/">https://eprints.aihta.at/1296/</a>
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)	published	39	2021	<a href="https://eprints.aihta.at/1297/">https://eprints.aihta.at/1297/</a>
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement	published	40	2021	<a href="https://eprints.aihta.at/1298/">https://eprints.aihta.at/1298/</a>
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)	published	41	2021	<a href="https://eprints.aihta.at/1299/">https://eprints.aihta.at/1299/</a>
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)	published	42	2021	<a href="https://eprints.aihta.at/1300/">https://eprints.aihta.at/1300/</a>
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)	published	43	2021	<a href="https://eprints.aihta.at/1301/">https://eprints.aihta.at/1301/</a>
Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)	published	44	2021	<a href="https://eprints.aihta.at/1304/">https://eprints.aihta.at/1304/</a>
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)	published	45	2021	<a href="https://eprints.aihta.at/1305/">https://eprints.aihta.at/1305/</a>
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)	published	46	2021	<a href="https://eprints.aihta.at/1306/">https://eprints.aihta.at/1306/</a>
Azacitidine (Onureq®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)	published	47	2021	<a href="https://eprints.aihta.at/1309/">https://eprints.aihta.at/1309/</a>

Title	Status	No.	Year	Download/Link
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIa non-small cell lung cancer (NSCLC)	published	48	2021	<a href="https://eprints.aihta.at/1310/">https://eprints.aihta.at/1310/</a>
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)	published	49	2021	<a href="https://eprints.aihta.at/1311/">https://eprints.aihta.at/1311/</a>
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma	published	50	2021	<a href="https://eprints.aihta.at/1312/">https://eprints.aihta.at/1312/</a>
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer	published	51	2021	<a href="https://eprints.aihta.at/1315/">https://eprints.aihta.at/1315/</a>
Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)	published	52	2021	<a href="https://eprints.aihta.at/1316/">https://eprints.aihta.at/1316/</a>
Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)	published	53	2021	<a href="https://eprints.aihta.at/1317/">https://eprints.aihta.at/1317/</a>
Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus	published	54	2021	<a href="https://eprints.aihta.at/1318/">https://eprints.aihta.at/1318/</a>
Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	55	2021	<a href="https://eprints.aihta.at/1319/">https://eprints.aihta.at/1319/</a>
Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis	published	56	2021	<a href="https://eprints.aihta.at/1320/">https://eprints.aihta.at/1320/</a>
Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)	published	57	2021	<a href="https://eprints.aihta.at/1330/">https://eprints.aihta.at/1330/</a>
Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	published	58	2021	<a href="https://eprints.aihta.at/1331/">https://eprints.aihta.at/1331/</a>
Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)	published	59	2021	<a href="https://eprints.aihta.at/1332/">https://eprints.aihta.at/1332/</a>
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström's macroglobulinaemia (WM)	published	60	2021	<a href="https://eprints.aihta.at/1336/">https://eprints.aihta.at/1336/</a>
Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)	published	61	2021	<a href="https://eprints.aihta.at/1337/">https://eprints.aihta.at/1337/</a>
Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)	published	62	2021	<a href="https://eprints.aihta.at/1338/">https://eprints.aihta.at/1338/</a>
Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 <sup>+</sup> negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	published	63	2021	<a href="https://eprints.aihta.at/1339/">https://eprints.aihta.at/1339/</a>
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)	published	64	2021	<a href="https://eprints.aihta.at/1340/">https://eprints.aihta.at/1340/</a>
	laufend	65		
	laufend	66		
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)	published	67	2021	<a href="https://eprints.aihta.at/1343/">https://eprints.aihta.at/1343/</a>
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)	publiziert	68	2021	<a href="https://eprints.aihta.at/1344/">https://eprints.aihta.at/1344/</a>
Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)	publiziert	69	2021	<a href="https://eprints.aihta.at/1345/">https://eprints.aihta.at/1345/</a>
Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)	publiziert	70	2021	<a href="https://eprints.aihta.at/1346/">https://eprints.aihta.at/1346/</a>
Sotorasib (Lumykras®); Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation	publiziert	71	2021	<a href="https://eprints.aihta.at/1347/">https://eprints.aihta.at/1347/</a>
<b>Other Reports/ Projects</b>				
Annual Report 2006. German version.	published		2007	<a href="http://eprints.hta.lbg.ac.at/781/">http://eprints.hta.lbg.ac.at/781/</a>
Annual Report 2006. English version.	published		2007	<a href="http://eprints.hta.lbg.ac.at/786/">http://eprints.hta.lbg.ac.at/786/</a>
Annual Report 2007. German version.	published		2008	<a href="http://eprints.hta.lbg.ac.at/782/">http://eprints.hta.lbg.ac.at/782/</a>
Annual Report 2007. English version.	published		2008	<a href="http://eprints.hta.lbg.ac.at/785/">http://eprints.hta.lbg.ac.at/785/</a>
Annual Report 2008. German version.	published		2009	<a href="http://eprints.hta.lbg.ac.at/819/">http://eprints.hta.lbg.ac.at/819/</a>
Annual Report 2008. English version.	published		2009	<a href="http://eprints.hta.lbg.ac.at/821/">http://eprints.hta.lbg.ac.at/821/</a>
Annual Report 2009. German version.	published		2010	<a href="http://eprints.hta.lbg.ac.at/871/">http://eprints.hta.lbg.ac.at/871/</a>
Annual Report 2009. English version.	published		2010	<a href="http://eprints.hta.lbg.ac.at/872/">http://eprints.hta.lbg.ac.at/872/</a>
Annual Report 2010. German version.	published		2011	<a href="http://eprints.hta.lbg.ac.at/904/">http://eprints.hta.lbg.ac.at/904/</a>
Annual Report 2010. English version.	published		2011	<a href="http://eprints.hta.lbg.ac.at/909/">http://eprints.hta.lbg.ac.at/909/</a>
Annual Report 2011. German version.	published		2012	<a href="http://eprints.hta.lbg.ac.at/943/">http://eprints.hta.lbg.ac.at/943/</a>
Annual Report 2011. English version.	published		2012	<a href="http://eprints.hta.lbg.ac.at/944/">http://eprints.hta.lbg.ac.at/944/</a>
"Institut für Health Technology Assessment" unter Mitfinanzierung der Ludwig Boltzmann Gesellschaft 2013-2020	finished		2010	not published
"Institute for Health Technology Assessment" with Co-financing of the Ludwig Boltzmann Gesellschaft 2013 bis 2020	finished		2011	not published
Annual Report 2012. German/English	published		2013	<a href="http://eprints.hta.lbg.ac.at/991/">http://eprints.hta.lbg.ac.at/991/</a>

## HTA Austria, Austrian Institute for Health Technology Assessment

Title	Status	No.	Year	Download/Link
Annual Report 2013. German/English	published		2014	<a href="http://eprints.hta.lbg.ac.at/1022/">http://eprints.hta.lbg.ac.at/1022/</a>
Annual Report 2014. German/English	published		2015	<a href="http://eprints.hta.lbg.ac.at/1048/">http://eprints.hta.lbg.ac.at/1048/</a>
Annual Report 2015. German/English	published		2016	<a href="http://eprints.hta.lbg.ac.at/1083/">http://eprints.hta.lbg.ac.at/1083/</a>
Annual Report 2016. German/English	published		2017	<a href="http://eprints.hta.lbg.ac.at/1150/">http://eprints.hta.lbg.ac.at/1150/</a>
Annual Report 2017. German/English	published		2018	<a href="http://eprints.hta.lbg.ac.at/1151/">http://eprints.hta.lbg.ac.at/1151/</a>
Annual Report 2018. German/English	published		2019	<a href="http://eprints.hta.lbg.ac.at/1187/">http://eprints.hta.lbg.ac.at/1187/</a>
Annual Report 2019. German/English	published		2020	<a href="http://eprints.hta.lbg.ac.at/1226/">http://eprints.hta.lbg.ac.at/1226/</a>
Annual Report 2020. German/English	published		2021	<a href="https://eprints.aihta.at/1294/">https://eprints.aihta.at/1294/</a>
EUnetHTA (European network for Health Technology Assessment) Joint Action 1 - Lead Partner Work package 7B - New Technologies	ongoing		2006-2008, 2009, 2010-2013	<a href="http://www.eunetha.eu/">www.eunetha.eu/</a>
EUnetHTA (European network for Health Technology Assessment) Joint Action 2 - Colead Partner Work package 5 - Collaboration	ongoing		2012-2015	<a href="http://www.eunetha.eu/">www.eunetha.eu/</a>
AdHopHTA	ongoing		2012-2015	<a href="http://www.adhophta.eu/">http://www.adhophta.eu/</a>
HSO Priorisation No. 18	published		2014	<a href="http://eprints.hta.lbg.ac.at/1026/">http://eprints.hta.lbg.ac.at/1026/</a>
HSO Priorisation No. 19	published		2014	<a href="http://eprints.hta.lbg.ac.at/1033/">http://eprints.hta.lbg.ac.at/1033/</a>
HSO Priorisation No. 20	published		2014	<a href="http://eprints.hta.lbg.ac.at/1040/">http://eprints.hta.lbg.ac.at/1040/</a>
HSO Priorisation No. 21	published		2015	<a href="http://eprints.hta.lbg.ac.at/1046/">http://eprints.hta.lbg.ac.at/1046/</a>
HSO Priorisation No. 22	published		2015	<a href="http://eprints.hta.lbg.ac.at/1052/">http://eprints.hta.lbg.ac.at/1052/</a>
HSO Priorisation No. 23	published		2015	<a href="http://eprints.hta.lbg.ac.at/1065/">http://eprints.hta.lbg.ac.at/1065/</a>
HSO Priorisation No. 24	published		2015	<a href="http://eprints.hta.lbg.ac.at/1074/">http://eprints.hta.lbg.ac.at/1074/</a>
HSO Priorisation No. 25	published		2016	<a href="http://eprints.hta.lbg.ac.at/1079/">http://eprints.hta.lbg.ac.at/1079/</a>
HSO Priorisation No. 26	published		2016	<a href="http://eprints.hta.lbg.ac.at/1087/">http://eprints.hta.lbg.ac.at/1087/</a>
HSO Priorisation No. 27	published		2016	<a href="http://eprints.hta.lbg.ac.at/1099/">http://eprints.hta.lbg.ac.at/1099/</a>
HSO Priorisation No. 28	published		2016	<a href="http://eprints.hta.lbg.ac.at/1106/">http://eprints.hta.lbg.ac.at/1106/</a>
HSO Priorisation No. 29	published		2017	<a href="http://eprints.hta.lbg.ac.at/1113/">http://eprints.hta.lbg.ac.at/1113/</a>
HSO Priorisation No. 30	published		2017	<a href="http://eprints.hta.lbg.ac.at/1117/">http://eprints.hta.lbg.ac.at/1117/</a>
HSO Priorisation No. 31	published		2017	<a href="http://eprints.hta.lbg.ac.at/1121/">http://eprints.hta.lbg.ac.at/1121/</a>
HSO Priorisation No. 32	published		2017	<a href="http://eprints.hta.lbg.ac.at/1133/">http://eprints.hta.lbg.ac.at/1133/</a>
HSO Priorisation No. 33	published		2018	<a href="http://eprints.hta.lbg.ac.at/1135/">http://eprints.hta.lbg.ac.at/1135/</a>
HSO Priorisation No. 34	published		2018	<a href="http://eprints.hta.lbg.ac.at/1149/">http://eprints.hta.lbg.ac.at/1149/</a>
HSO Priorisation No. 35	published		2018	<a href="http://eprints.hta.lbg.ac.at/1156/">http://eprints.hta.lbg.ac.at/1156/</a>
HSO Priorisation No. 36	published		2018	<a href="http://eprints.hta.lbg.ac.at/1156/">http://eprints.hta.lbg.ac.at/1156/</a>
HSO Priorisation No. 37	published		2018	<a href="http://eprints.hta.lbg.ac.at/1179/">http://eprints.hta.lbg.ac.at/1179/</a>
HSO Priorisation No. 38	published		2019	<a href="http://eprints.hta.lbg.ac.at/1189/">http://eprints.hta.lbg.ac.at/1189/</a>
HSO Priorisation No. 39	published		2019	<a href="http://eprints.hta.lbg.ac.at/1196/">http://eprints.hta.lbg.ac.at/1196/</a>
HSO Priorisation No. 40	published		2019	<a href="http://eprints.hta.lbg.ac.at/1208/">http://eprints.hta.lbg.ac.at/1208/</a>
HSO Priorisation No. 41	published		2020	<a href="http://eprints.hta.lbg.ac.at/1220/">http://eprints.hta.lbg.ac.at/1220/</a>